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Background: Interventions to improve fecal testing for colorectal cancer (CRC) exist, but are not yet routine
practice. We conducted this systematic review to determine how implementation strategies and contextual
factors influenced the uptake of interventions to increase Fecal Immunochemical Tests (FIT) and Fecal Occult
Blood Testing (FOBT) for CRC in rural and low-income populations in the United States.
Methods: We searched Medline and the Cochrane Library from January 1998 through July 2016, and Scopus
and clinicaltrials.gov through March 2015, for original articles of interventions to increase fecal testing for CRC.
Two reviewers independently screened abstracts, reviewed full-text articles, extracted data and performed
quality assessments. A qualitative synthesis described the relationship between changes in fecal testing rates
for CRC, intervention components, implementation strategies, and contextual factors. A technical expert panel
of primary care professionals, health system leaders, and academicians guided this work.
Results: Of 4218 citations initially identified, 27 unique studies reported in 29 publications met inclusion criteria.
Studies were conducted in primary care (n = 20, 74.1%), community (n = 5, 18.5%), or both (n = 2, 7.4%) settings.
All studies (n = 27, 100.0%) described multicomponent interventions. In clinic based studies, components that
occurred most frequently among the highly effective/effective study arms were provision of kits by direct mail,
use of a pre-addressed stamped envelope, client reminders, and provider ordered in-clinic distribution.
Interventions were delivered by clinic staff/community members (n = 10, 37.0%), research staff (n = 6, 22.2%), both
(n = 10, 37.0%), or it was unclear (n = 1, 3.7%). Over half of the studies lacked information on training or monitoring
intervention fidelity (n = 15, 55.6%).
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Conclusions: Studies to improve FIT/FOBT in rural and low-income populations utilized multicomponent interventions.
The provision of kits through the mail, use of pre-addressed stamped envelopes, client reminders and in-clinic
distribution appeared most frequently in the highly effective/effective clinic-based study arms. Few studies
described contextual factors or implementation strategies. More robust application of guidelines to support
reporting on methods to select, adapt and implement interventions can help end users determine not just which
interventions work to improve CRC screening, but which interventions would work best in their setting given specific
patient populations, clinical settings, and community characteristics.
Trial registration: In accordance with PRISMA guidelines, our systematic review protocol was registered with
PROSPERO, the international prospective register of systematic reviews, on April 16, 2015 (registration number
CRD42015019557).
Keywords: Systematic review, Colorectal cancer, Fecal testing, Implementation science, Rural, Vulnerable
populationsBackground
Colorectal cancer (CRC) is the third most common
cancer, and the second leading cause of cancer deaths,
in the United States [1]. Unequivocal evidence demon-
strates that guideline concordant screening decreases
CRC incidence and mortality by 30–60% [2]. Numer-
ous modalities are currently recommended for CRC
screening in average risk adults aged 50–75 years, in-
cluding colonoscopy every 10 years or a fecal occult
blood test (FOBT) or fecal immunochemical test (FIT)
within the past year [3–5]. However, current CRC
screening rates are 63% across the United States [6],
well below targets set by the National CRC Roundtable
(80% by 2018) [7] and by Healthy People 2020 (70.5%)
[8]. More striking are the consistent disparities in CRC
screening in rural areas, among adults with low
income, and in racial and ethnic minorities [6, 9–12].
Although improving, screening rates in these
vulnerable populations may be 15%–30% lower than
their non-rural, higher income, non-minority counter-
parts [13].
Multiple systematic reviews identify interventions that
effectively increase CRC screening [14–16]. In 2016, the
Community Preventive Services Task Force recommended
the use of multicomponent interventions to increase
screening for CRC. Multicomponent interventions com-
bine two or more approaches to increase community
demand (e.g., client reminders, small media), community
access (e.g., reducing client costs), or provider delivery of
screening services (e.g., provider reminders) or two or
more approaches to reduce different structural barriers
[17]. However, understanding how these interventions can
be best implemented and in what populations (e.g., screen-
ing naïve versus experienced) and settings (e.g., rural versus
urban settings, health system versus independent clinics)
remains a neglected area of study [14, 18, 19].
Implementing interventions into routine care in clinic
and community-based settings often involves the activeengagement of multiple stakeholders and the adaptation
of program elements to local contexts. In Oregon and
elsewhere, primary care and health plan leaders are
eager to identify, adapt, and implement interventions to
improve CRC screening in order to achieve state per-
formance benchmarks and to improve patient quality
and experience of care. However, our work with primary
care and health system partners found that stakeholders
are interested not just in which interventions work to
improve CRC screening, but which interventions would
work best in their setting given specific patient popula-
tions, clinical settings, and community characteristics
(see www.communityresearchalliance.org).
Therefore, we designed this systematic review to com-
pare the effectiveness of interventions to improve fecal
testing for CRC in clinic and community settings serving
rural, low-income populations and their associated im-
plementation strategies and contextual factors (see defi-
nitions and sources, Fig. 1) [17, 30, 32–37]. Determining
how implementation strategies and contextual factors
influence the uptake of interventions to increase fecal
testing for CRC may help stakeholders identify the inter-
ventions best suited for use in their local settings.
We focused on fecal testing because this modality
plays an important role in early detection of CRC, par-
ticularly in population groups at risk for experiencing
disparities. Despite the increasing transition to FIT as
the preferred modality for fecal testing due to superior
adherence, usability, and accuracy [20, 21], we included
studies of FOBT as well based on feedback from our
technical expert panel (which included primary care pro-
fessionals, health system leaders, and academicians) that
early research on interventions to increase FOBT would
likely inform current efforts to increase FIT [22–24].
Our key questions were:
1. What is the effectiveness of various interventions to
increase CRC screening with FIT/FOBT compared
Fig. 1 Definitions of Key Terms: Multicomponent Interventions, Implementation Strategies, and Contextual Factors
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low-income populations?
2. How do implementation strategies (e.g., clinician
champions, external practice facilitation) influence
the effectiveness of interventions to increase FIT/
FOBT screening for CRC in rural or low-income
populations?
3. How do contextual factors (e.g., patient, clinic,
community features) influence the effectiveness of
interventions to increase FIT/FOBT screening for
CRC in rural or low-income populations?
4. What are the adverse effects of interventions to
increase FIT/FOBT screening for CRC in rural or
low-income populations?
Methods
We followed systematic review methods described in the
Cochrane Handbook for Systematic Reviews of Interven-
tions [25] and AHRQ [26]. The review was guided by a
technical expert panel of primary care professionals,
health system leaders, and academicians. Our protocol
was registered with PROSPERO, the internationalprospective register of systematic reviews (registration
number CRD42015019557). The review is reported in
accordance with the PRISMA publication standards
[27–29].
Search strategy
We developed our search strategy with a research librar-
ian with keywords for colorectal cancer, screening, stool,
and FIT or FOBT (Additional file 1: Appendix A). We
searched MEDLINE®, Cochrane Library, Scopus, and
clinicaltrials.gov from January 1, 1998 through March
31, 2015, and updated our search of MEDLINE® and the
Cochrane Library on July 19, 2016. Additionally, we
reviewed reference lists of included studies and relevant
systematic reviews.
Study selection
We screened studies using specific inclusion criteria
detailed in Additional file 1: Appendix B. Included stud-
ies targeted patients aged 50–75 years, occurred in set-
tings serving rural, Medicaid, or lower socioeconomic
status populations in the United States, and reported
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cluded randomized controlled trials, non-randomized
controlled trials, cohort studies, and pre-post studies.
Two research members (MMD, MF) screened titles and
abstracts for eligibility; and then obtained the full-text of
potentially eligible citations for further evaluation. Two
investigators independently reviewed the full articles to
determine final inclusion, with differences resolved
through consensus or inclusion of a third investigator.
Data abstraction
Data from included studies were abstracted into a cus-
tomized Microsoft Excel Spreadsheet by one investigator
and reviewed for accuracy and completeness by a second
investigator. Our overall analytic framework was
informed by the Consolidated Framework for Implemen-
tation Research (CFIR) [30] and recent reviews on com-
plex multicomponent interventions [18, 31]. Information
was abstracted from each study on study setting, design,
intervention attributes (e.g., intervention arms tested,
type of FIT/FOBT used, theoretical framework), and
study results (CRC screening rates, impact by interven-
tion component, recruitment success). Additionally, for
each intervention arm tested in an included study we
categorized intervention components into distinct, indi-
vidual categories starting with the Community Prevent-
ive Services Task Force recommendations for CRC
screening (see Fig. 1) and refined based on study find-
ings (e.g., 5 individual sub-categories identified under
reducing structural barriers) [17].
We attempted to abstract data related to implementa-
tion strategies and contextual factors when feasible (see
Fig. 1). Specifically, we tried to catalogue implementation
strategies according to recent work by Proctor, Powell,
and colleagues, which encourages the identification of
discrete strategies and documentation of elements such as
the actor, action, action targets, dose, and theoretical justi-
fication [30, 32–34]. We also attempted to classify con-
textual factors based on work by Stange and colleagues
focused on the identification of factors across multiple
levels (e.g., patient, practice, organization, and environ-
ment), the motivation for the intervention, and change in
context over time [35–37]. However, a paucity of detail in
the manuscripts led us to abstract any information regard-
ing implementation strategies and contextual factors in a
figure summary, rather than as discrete components as
originally planned. Disagreements were resolved by
discussion; one author (DIB) adjudicated decisions as
needed.
Risk of bias/quality assessment
Two authors independently assessed the quality of each
included study. We used a tool developed by the
Cochrane Collaboration for randomized controlled trialsand control trial designs [25]. We used a tool developed
by the National Institutes of Health for quality assess-
ment in pre-post studies which included questions about
pre-specification of study details (e.g., aims, eligibility
criteria, outcome measures) and methods for data col-
lection and analysis (e.g., method for outcome assess-
ment, analysis controlled for clustering) [38, 39] We did
not assess the quality of feasibility studies because no
validated criteria are available. Rated studies were given
an overall summary assessment of “low”, “high”, or “un-
clear” risk of bias. Disagreements were resolved through
discussion.
Data synthesis
We constructed evidence tables showing the study charac-
teristics and results for included studies by key question.
We clustered studies based on the (1) intervention setting:
primary care clinic, community-based settings, or both
and (2) intervention components used in each study arm
(e.g., client reminder or recall, small media, provider in-
centives). We assessed the effectiveness of the study arms
based on the percent of CRC screening completion in the
intervention arms compared with the control/usual care
arm. We categorized the study arms as being highly effect-
ive if screening at the end of follow-up was higher in treat-
ment than the usual care/control condition by more than
25%; effective if the difference was 10–25%; marginally
effective if there was an increase of less than 10%; or hav-
ing no effect. We developed this categorization based on
the proportional distribution of the outcome and author
assessments of clinical significance. We then assessed
which intervention components occurred more frequently
among the effective and highly effective study arms, com-
pared with intervention arms that had little or no effect.
Finally, we assessed studies to compare their intervention
components, implementation strategies, contextual fac-
tors, methods, and findings. We compiled a summary of
findings for each key question and drew conclusions based
on qualitative synthesis of the findings. We did not com-
bine the studies in a quantitative manner via meta-
analysis because of the heterogeneity of interventions,
methods, and settings.
Rating the body of evidence
We attempted to grade the overall strength of the
evidence as high, moderate, low, or insufficient using a
method developed by AHRQ [26]. This method con-
siders the consistency, coherence, and applicability of a
body of evidence, as well as the internal validity of indi-
vidual studies. However, because the studies used multi-
component interventions and did not assess the
effectiveness of individual components, we were limited
from applying AHRQ criteria to the strength of evidence
for the individual intervention components.
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The combined literature searches initially yielded 4218
titles and abstracts, including 4203 from electronic data-
base searches, and 15 from reference lists of systematic
reviews and other relevant articles. As summarized in
Fig. 2, we assessed 278 full-text articles for eligibility, of
which 27 studies reported in 29 publications met inclu-
sion criteria. We identified 20 RCTs (published in 21
articles [40–60], 2 non-randomized controlled trials [61,
62], 3 pre-post studies [63–65], 1 cohort study [66] and
1 feasibility study [67] that contained primary data rele-
vant to the key questions. The descriptive characteristics
and findings of the 27 included studies are found in
Additional file 1: Appendix D, Table D1.
Studies occurred in primary care clinics (n = 20, 74.1%),
communities (n = 5, 18.5%), or in both settings (n = 2,
7.4%). Over half of the studies used FOBT (n = 18, 66.6%);
FIT was used in 8 studies (29.6%); one study used both
FIT and FOBT (3.7%). As summarized in Additional file 1:
Appendix D, Table D2, patient eligibility and the informed
consent process varied across the studies. Of the 20 clinic-
based studies, 5 (25%) did not report on the patient con-
sent process, 8 (40%) received a waiver of informed
consent, 4 (20%) utilized an informed consent process, 2
(10%) used opt-out, and 1 was conducted as a quality
improvement study (5%). Six of the seven studies (85.7%)
conducted in community or both clinic/community4,203 Citations identified from electronic database
2,851 from Ovid MEDLINE® on 6/30/2016
469 from Cochrane libraries (CCRCT, D
883 from SCOPUS 1998-2015 on 4/09/2
15 Citations identified
4,218 Citations compiled for review of titl
278 Potentially relevant articles retrieved fo
249 Excluded artic
Study populati
No primary da
Treatment com
Reported outco
Systematic rev
Retrieved for b
27 Primary studies published in
29 articles
23
4
Fig. 2 Literature Flow Diagramsettings did not report on the patient consent process;
the one remaining study required informed consent.
Many of the included studies rated as high or unclear
risk of bias, this was often related to insufficient de-
tail in the methods as well as lack of blinding. Qual-
ity assessment details appear in Additional file 1:
Appendix C, Tables C1 and C2.
Interventions and effectiveness
Study-level
All studies (n = 27, 100.0%) described multicomponent in-
terventions. As presented in Additional file 1: Appendix
D, Table D3, the majority of studies used some form of
strategy to increase community demand (n = 25, 92.6%)
and/or to increase community access (n = 24, 88.9%) in
the most complex intervention arm. Commonly used
intervention components to increase community demand
included small media (n = 17, 63.0%), client reminder or
recall (n = 16, 59.3%), and one-on-one education (n = 14,
51.9%). Strategies to reduce structural barriers included
increasing in-clinic distribution of FIT/FOBT by pro-
viders (n = 11, 40.7%) or clinical staff/research team
members (n = 12, 44.4%), programs that mailed FIT/
FOBT materials directly to the patient’s home (n = 10,
37.0%, aka “direct mail programs”), provision of pre-
addressed stamped envelopes to facilitate return of
the completed FIT/FOBT (n = 12, 44.4.7%), or FIT/ searches 
SR, DARE) on 7/05/2016
015 
 from reference lists of review articles
es and abstracts
3,940 Excluded for lack of relevance
r further review
les:
on not in scope: 70
ta or excluded study design: 17
parison or study objectives not in scope: 21
mes not in scope: 3
iew used for identifying additional studies: 11
ackground, discussion, or methods: 127
Controlled trials:
21 Randomized
2 Non-randomized
Other study designs:
3 Pre-post
1 Feasibility assessment
Table 1 Number of study arms using specified intervention
components among clinic- based, community-based, and both
clinic/community-based studies
Intervention components
grouped by strategic aim
Active intervention arms grouped by
study setting
Referent group
(usual care/
control arm)
Clinic-based Community-
based
Combined Clinic/
Community-based
Increase Community Demand
Client reminder or
recall
16 1 2 1
Client incentives 0 0 1 0
Small media 16 5 4 3
Mass media 0 0 2 0
Group education 0 6 1 1
One-on-one education 11 4 3 3
Increase Community Access
Reducing structural
barriers
▪ Provider ordered in-
clinic distribution
14 1 0 12
▪ Systematic
distribution by clinic
staff or study team
10 2 3 7
▪ Direct mail 13 0 0 0
▪ Pre-addressed
stamped envelope
provided
15 1 0 1
▪ Kit available by
participant request
2 1 1 1
Reducing client out-
of-pocket costs
1 2 4 1
Increase Provider Delivery of Screening Services
Provider assessment
and feedback
3 0 0 2
Provider incentives 2 0 0 2
Provider reminder and
recall systems
6 0 0 1
Other
Patient navigators 10 1 4 0
Patient questionnaires
or surveys about CRC
screening knowledge
and behaviors
5 2 0 6
Materials tailored for
specific cultures or low
literacy
11 0 0 2
Leveraging social
networks
0 4 0 0
Total number of studies 20 5 2 *
Total number of study
arms
27 7 4 *
* N control arms: N = 20 among 20-clinic based studies; N = 4 among 5 community-
based studies; N = 0 in 2 combined clinic/community-based studies
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14.8%). Each of the 10 studies that used a direct mail
program also utilized client reminder and recall. Al-
though 12 studies used pre-addressed stamped enve-
lopes, this intervention component was only
employed in 70% (7/10) of the studies using a direct
mail program (see Additional file 1: Appendix D,
Table D3). Many studies also used patient navigators
(n = 12, 44.4%) or other miscellaneous intervention
components (n = 17, 63.0%) such as by providing
culturally tailored materials or having participants
complete surveys about CRC screening knowledge
and behaviors.
Study arm-level
As summarized in Table 1, most studies tested multi-
component interventions in varied combinations across
multiple study arms. Among the 20 clinic-based studies
[40, 43–58, 60, 61, 64, 66], there were 27 active treat-
ment arms. The most frequently used intervention com-
ponents in clinic-based treatment arms included client
reminder or recall (16/27, 59.3%,), small media (16/27,
59.3%), provision of pre-addressed stamped envelopes
(15/27, 55.6%), and direct mail programs (13/27, 48.1%).
No clinic-based treatment arms used client incentives,
mass media, or group education. Over half (60%, 12/20)
of the control arms in the clinic-based studies distrib-
uted FIT/FOBT kits upon order by clinicians as part of
usual care.
Among the seven studies conducted either in commu-
nity settings [41, 42, 59, 63, 65] or that targeted both
clinic and community settings [62, 67], there were 11 ac-
tive treatment arms. Group education (n = 7, 63.6%),
small media (n = 9, 81.8%), and one-on-one education
(n = 7, 63.6%) were the most frequently used interven-
tion components used in these settings. The strategy of
leveraging social networks was only used in community-
based studies.
All studies that included highly effective treatment
arms were clinic-based. In these clinic-based studies, 9
treatment arms were rated as highly effective (greater
than 25% higher screening rate compared with the con-
trol/usual care group), and 12 treatment arms were rated
as effective (10% to 25% higher screening rate compared
with control/usual care group). As detailed in Table 2,
the components that occurred most frequently among
the highly effective and effective study arms were
provision of kits by direct mail, provision of a pre-
addressed stamped envelope, client reminder or recall,
and provider ordered in-clinic distribution. Additionally,
some studies used a layered approach, by adding inter-
vention components among multiple study arms, or by
adding successive interventions within a single interven-
tion arm in an attempt to reach non-responders. Studieswith highly effective treatment arms occurred in a var-
iety of ethnic populations, however, most of these stud-
ies occurred in urban areas (6 of 7 studies).
Among 10 studies that used direct mailing of the FIT/
FOBT as an intervention strategy [40, 43, 46, 47, 49, 50,
52, 54, 55, 58, 61], the mailed kit plus 1–3 phone
Table 2 Effectiveness of intervention components to improve fecal testing for CRC among clinic-based study arms, N (%)
Intervention components grouped by strategic aim Active intervention arms
grouped by effectiveness, N (%)a
Referent
group (usual care/
control arms)Highly effective Effective Marginal/
null effect
Increase Community Demandb
Client reminder or recall 7 (77.8) 7 (58.3) 2 (33.3) 0 (0.0)
Small media 5 (55.6) 6 (50.0) 5 (83.3) 2 (10.0)
One-on-one education 3 (33.3) 4 (33.3) 4 (66.7) 2 (10.0)
Increase Community Access
Reducing structural barriers
▪ Provider ordered in-clinic distribution 7 (77.8) 6 (50.0) 1 (16.7) 12 (60.0)
▪ Systematic distribution by clinic staff study team 2 (22.2) 5 (41.7) 3 (50.0) 6 (30.0)
▪ Direct mail 8 (88.9) 5 (41.7) 0 (0.0) 0 (0.0)
▪ Pre-addressed stamped envelope provided 8 (88.9) 5 (41.7) 2 (33.3) 1 (5.0)
▪ Kit available by participant request 1 (11.1) 0 (0.0) 1 (16.7) 1 (5.0)
Reducing out-of-pocket costs 0 (0.0) 1 (8.3) 0 (0.0) 1 (5.0)
Increase Provider Delivery of Screening Services
Provider assessment and feedback 1 (11.1) 2 (16.7) 0 (0.0) 2 (10.0)
Provider incentives 1 (11.1) 1 (8.3) 0 (0.0) 2 (10.0)
Provider reminder and recall systems 3 (33.3) 2 (16.7) 1 (16.7) 1 (5.0)
Other c
Patient navigators 4 (44.4) 4 (33.3) 2 (33.3) 0 (0.0)
Patient questionnaires or surveys about CRC screening knowledge
and behaviors
0 (0.0) 2 (16.7) 3 (50.0) 3 (15.0)
Materials tailored for specific cultures or low literacy 5 (55.6) 5 (41.7) 1 (16.7) 2 (10.0)
Total combined study arms in 20 clinic-based studies 9 (100.0) 12 (100.0) 6 (100.0) 20 (100.0)
Average number of intervention components per study arm 6.0 4.6 4.0 1.7
a Percent of the total number of study arms in each column
b We do not report on client incentives, mass media, group education because these intervention components were not used in clinic-based studies
c We do not report on leveraging social networks because this intervention component was not used in clinic-based studies
Davis et al. BMC Cancer  (2018) 18:40 Page 7 of 16reminders were more effective than usual care in in-
creasing FIT/FOBT use; the frequency of FIT/FOBT
completion in the intervention arms ranged from 29% to
82% compared with 1.1% to 37% in the control arms. In-
tensive outreach using navigators (e.g., home visits,
phone calls) was used as a core component of some
study interventions [49, 51–53], as a more complex
study intervention arm [44, 54, 55, 61], or as a technique
for reaching non-responders in layered interventions
[40, 47]. FIT/FOBT completion among non-responders
generally remained lower after outreach compared with
early responders. The overall effectiveness of intensive
outreach compared with minimal or automated phone/
text outreach was not consistent across studies. Our data
suggest that effectiveness may relate to the timing at which
navigation was delivered (e.g., early on as a core compo-
nent of the initial intervention or as a follow-up strategy
used with non-responders to another intervention).Contextual factors
Few studies provided details on contextual factors beyond
the study location or the population of interest, see sum-
mary in Table 3 (details in Additional file 1: Appendix D,
Table D4). Twenty (74%) of the 27 studies were conducted
in urban settings, five studies (18.5%) were conducted in
rural settings and one did not designate a geographic
setting (3.7%). Of the five studies conducted in rural set-
tings, three occurred in primary care clinics and two were
based in the community. Of the 20 studies conducted in
clinics, 14 (70.0%) occurred in clinics affiliated with a lar-
ger system (e.g., hospital, FQHC, health department), two
occurred in clinics affiliated with practice-based research
networks (10.0%), two in independent clinics (10.0%), and
two could not be determined (10.0%). Irrespective of study
setting as detailed in Additional file 1: Appendix D,
Table D4, very limited details, if any, were provided about
organizational priorities or environmental factors that
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Davis et al. BMC Cancer  (2018) 18:40 Page 10 of 16may have influenced a site’s interest in participating in the
study. A few studies built on existing community-based
programs [65], quality improvement initiatives [40, 47], or
emerged based on community or health system identified
needs [62, 67].
Thirteen out of the 27 studies (48.1%) targeted pa-
tients of a specific race or ethnic group [40–43, 45–47,
59, 60, 62, 63, 65, 66] and six (22.2%) occurred in clinics
that largely served racial/ethnic minority or multicul-
tural patients [50, 52, 53, 56, 58, 64]. Five studies focused
on Latino populations, four were conducted in Asian pa-
tient populations, three focused on African Americans,
and one study was conducted among native Hawaiians
[41]. Of the six studies conducted in community settings
or both clinic/community settings, none reported on the
prior screening history of eligible patients (0%). Of the
20 clinic-based studies, 13 (65.0%) targeted patients who
were not-up-to-date with CRC screening [44, 45, 47–49,
51–56, 58, 61, 66]. Six studies (30.0%) did not specify
participant’s prior screening history and one (5.0%) tar-
geted patients who had completed a prior FOBT. Six of
the 20 clinic-based studies (30.0%) reported on CRC
screening rates within a clinic or health system prior to
the intervention [40, 44, 47, 52, 54, 55, 61], and two of
these studies occurred in the same health system [40,
47]. Baseline screening rates in these settings varied
widely, from 1 to 2% to 54.3%. In one study setting, the
health system had initiated work to improve CRC
screening prior to the current studies by reducing struc-
tural barriers, introducing audit and feedback, imple-
menting provider reminders, and using CRC as a quality
metric by which providers received incentive payments.
These changes had increased CRC screening from 17%
in 2007 to 43% in 2009 prior to any interventions facili-
tated by the study teams [40, 47].
None of the studies in community or both commu-
nity/clinic settings reported on use of an electronic
health record (EHR) system. In the 20 clinic-based stud-
ies, 10 had an EHR (3 specified, 7 unspecified), 7 were
unclear, 2 used both paper and an EHR, and 1 used
paper charts (see Table 3 and details in Additional file 1:
Appendix D, Table D4).
Implementation strategies
As summarized in Table 3 and detailed in Additional
file 1: Appendix D, Table D5, studies provided very
limited information on the methods used to encour-
age the adoption of the interventions into practice; it
was often hard to determine if any implementation
support occurred. Among clinic-based interventions, 8
(40.0%) did not report how the intervention was
developed, 4 (20.0%) used focus groups, interviews, or sur-
veys to inform intervention development, 4 (20.0%) were
based on a pilot or prior intervention, and 4 (20.0%) wereinformed by stakeholder input or other methods. In com-
munity and community/clinic-based studies, intervention
development was informed either by focus groups, inter-
views, or surveys (n = 3, 42.9%) or by stakeholder input or
other methods (n = 4, 57.1%).
Methods to support training on the intervention
and monitoring fidelity of the intervention compo-
nents over time was not reported for over half of the
27 studies (n = 15, 55.6%). Although training was
mentioned in 12 of these studies, the details provided
were often limited and varied widely: 6 (50.0%) did
not report on the length of training, 4 (33.3%) had
one session lasting 30 min to 2 h, 1 (8.3%) had a
2 day training, and 1 (8.3%) delivered multiple in-
service presentations to the medical assistants or
clinic staff. Potter et al. provided the most robust
description of their training which included a 1-h
training for nursing staff; onsite review of study pro-
cedures with individual nurses; frequent site-visits to
ensure nursing staff were aware of the week’s study
protocol; and daily availability of research assistants
to ask questions regarding study implementation [56].
Only six studies (22.2%) provided any data on moni-
toring intervention fidelity, which could include meet-
ings, observation visits, supervision, or random audits
with compliance feedback [52, 53, 56, 57, 61, 66].
Interventions were delivered by clinic staff, community
members, the research team, or a combination. Delivery
was unclear in one clinic-based study, the others were
almost equally distributed across the three categories: 7
(35.0%) were delivered by both clinic staff and the re-
search team, 6 (30.0%) by clinic staff, and 6 (30.0%) by
the research team. Community or community/clinic
studies were delivered by community members (n = 4,
57.1%) or by both community members and the research
team (n = 3, 42.9%). While few studies discussed strat-
egies to support implementation over time, Roetzheim
et al. [57] described routine feedback sessions with
research members and clinical staff 6 and 12 months
after the intervention had been implemented to discuss
intervention progress, challenges occurring, and what
could be done to improve implementation.
Seven studies provided highly heterogeneous informa-
tion on intervention costs [40, 42, 44, 46, 50, 57, 68], see
Additional file 1: Appendix D, Table D5. Some studies
providing data on the cost of individual intervention
components and others calculating the cost per patient
or per patients screened. Three studies determined inter-
vention costs per patient screened, which ranged from
$43 to $1688 [40, 44, 68].
Discussion
We found that studies to promote fecal testing in rural
and low-income populations used multicomponent
Davis et al. BMC Cancer  (2018) 18:40 Page 11 of 16interventions that were tested in varied combinations
across multiple study arms. Over half of the studies
(16/27, 59.3%) used an informed consent process or
did not provide details on the consent process, leav-
ing it difficult to interpret if the participating patients
were “different” than the general population served by
the clinic or in the community. The most frequently
used interventions in clinics included client reminder
or recall, small media, provision of pre-addressed
stamped envelopes for FIT/FOBT return, and direct
mail programs. Many studies also employed outreach
using navigators. In clinic-based studies, the compo-
nents that occurred most frequently among the highly
effective and effective study arms were provision of
kits by direct mail, use of a pre-addressed stamped
envelope, client reminders, and provider ordered in-
clinic distribution.
Few studies included an adequate description of the
contextual factors and approaches used to implement
the intervention needed for health system leaders, pri-
mary care providers, or researchers to replicate the study
in their own settings or to determine if the intervention
was a good “fit” for the local context. For example, only
25.9% (7/27) reported on baseline screening rates prior
to study implementation and only three clinic-based
studies (15.0%, 3/19) named the EHR system used. In re-
lation to implementation factors, delivery of the inter-
ventions occurred by clinic/community staff, research
team members, or both – yet over half of the studies did
not report on the type or length of training used. Few
studies indicated if new clinical staff were hired or add-
itional resources were provided to support intervention
implementation. Seven studies reported on intervention
costs, yet methods were heterogeneous, estimates highly
variable, and details inadequate for determining how
much an intervention might cost in a target setting.
Only six studies described monitoring intervention fidel-
ity, which was often limited to an acknowledgement
that some form of interaction between the study team
and clinical staff occurred (e.g., meetings,
supervision).
Our review describes the effectiveness of interven-
tions to improve fecal testing in low-income and rural
patients in clinic and community-based settings. As
in the recent review on CRC interventions by the
Community Preventive Services Task Force, we found
that most interventions tested in these settings were
multicomponent in nature (i.e., included two or more
strategies) [17]. Strategies to increase community de-
mand (i.e., client reminders) as well as to increase
community access (i.e., direct mail, use of a pre-
addressed stamped envelope, in-clinic distribution)
were intervention components commonly found in
highly effective/effective study arms tested in clinicsettings. However, generating precise estimates of spe-
cific intervention components was difficult in part
because of the limited information on baseline screen-
ing levels for participating clinics, different patient
targets (e.g., prior FIT/FOBT versus screening naïve),
and variation in the consent process (e.g., waived ver-
sus informed). Moreover, none of the articles included
in our review explicitly compared implementation
strategies or the impact of contextual factors on inter-
vention effectiveness.
One key challenge identified by our review was that
the articles frequently lacked information in relation to
local contextual factors and implementation strategies
that could be used to inform end users as to which inter-
ventions would work best in their setting given specific
patient populations, clinical settings, and community
characteristics – and how to implement them. In their
recent review to develop a taxonomy for CRC screening
promotion, Ritvo and colleagues emphasized the need to
describe the engagement sponsor, population targeted,
alternative screening tests, delivery methods, and sup-
port for test performance (EPADS) in future reporting
[69]. Numerous recent articles suggest strategies and ap-
proaches that can improve reporting of intervention
studies, including TIDieR (Template for Intervention
Description and Replication [70]) or PARIHS (Promot-
ing Action on Research Implementation in Health Ser-
vices [71]). Moreover, recent work by Powell and
colleagues identified 73 implementation strategies
grouped in 9 categories; thus providing a common
terminology that can be used to design and evaluate
effectiveness as well as implementation research studies
[32, 72]. However, as indicated in our review, this data is
either not being gathered by research investigators or it
is not being reported in publications.
We speculate that lack of reporting on the impact of
implementation strategies and contextual factors may
reflect funder preferences for novel discoveries, re-
searcher bias toward intervention effectiveness measured
by statistical significance rather than nuanced under-
standing of how, when, and why a specific intervention
works, and journal restrictions on manuscript length.
Our experience also suggests that pragmatic studies con-
ducted in settings serving rural and vulnerable popula-
tions are often better equipped for implementing
interventions owing to greater capacity for data report-
ing, workflow refinements, and leadership interest/en-
gagement than would be needed to scale these
interventions across average or “below average” settings.
This presents challenges and opportunities for cancer con-
trol researchers and implementation scientists. Namely, it
presents opportunities to compare the effectiveness of
implementation strategies needed to translate effective
multicomponent interventions into diverse clinic,
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signs to test stepped-implementation support in response
to baseline setting capacity and intervention responsive-
ness over time; and to implement “layered” interventions
which may first build clinic capacity and visit-based work-
flows prior to implementing population outreach pro-
grams [73].
We are seeing a shift to address these needs through
funding opportunities through the Cancer Moonshot, in
NCI and CDC’s continued support of collaborative re-
search networks and implementation research, as well as
the emergence of local initiatives in response to ad-
vanced payment models that reward improved CRC
screening and disparities reduction [74, 75]. Taking the
next step forward in implementation of evidence-based
approaches to improve cancer screening also argues for
investing in academic-community collaborations before
research studies begin through the infrastructure of
practice-based research networks [76], researcher in resi-
dence models [77], or participatory research methods
[78, 79]. Such partnered approaches can help actualize
the call for rapid and relevant science [80]. Shifting the
research paradigm to support collaborative, partnered
implementation enables leveraging “teachable moments”
and “tipping points” when research evidence can be used
to inform local, regional, or system-wide interventions
that are under consideration or actively underway.
There are a few important limitations in the present
study. First, we limited our review to studies targeting
rural and low-income patients in the United States.
These populations experience CRC screening disparities,
and our stakeholder partners wanted to know what
interventions worked best for settings serving these pa-
tients. It is also possible that interventions that are
effective for these hard-to-reach populations need to be
different or more intensive than those implemented in
higher resourced populations. Second, we acknowledge
that the requirement to have quantitative outcome data
on changes in FIT/FOBT may have led to the exclusion
of studies targeting any type of CRC screening or to
studies focused on qualitative methods. Future system-
atic reviews on this topic would benefit from interviews
with the lead or senior author or a realist review [81–83]
which could generate a more contextualized understand-
ing of how and why complex interventions achieve par-
ticular effects in particular contexts. Finally, we created
cut-offs for evaluating the individual intervention com-
ponents based on a proportional distribution of the out-
comes. This approach identified four intervention
components that commonly appeared in the highly ef-
fective/effective study arms in clinic based studies (i.e.,
direct mail, client reminders, addressed stamped enve-
lopes, in-clinic distribution); the use of alternative cut-
points may have identified additional strategies. Despitethese limitations, our findings document the general
deficiency in reporting on contextual factors, implemen-
tation strategies, and how these factors interact with the
intervention. Our review provides a critical starting
point for future reviews and informs research funding
and publication in this area.
There is growing interest in the conduct and reporting
of pragmatic research that can be used by stakeholders
to inform practice in primary care and community
settings. Such evidence can guide health systems admin-
istrators in selecting an appropriate intervention in their
setting, as well as approaches for adapting a given inter-
vention or implementation approach based on context-
ual factors. Interventions to improve FIT/FOBT for CRC
screening should be considered generally as complex in-
terventions (e.g., multicomponent, context-sensitive, and
highly dependent on the behaviors of participants and
providers) [84]. As the field of pragmatic research con-
tinues to advance, our findings suggest that the use of
standard guidelines for the reporting of implementation
strategies and contextual factors within trials may be
useful. Building on the policy of the National Institute of
Health (NIH) to require detailed on rigor and reproduci-
bility in grant submissions [85], journals, editors, and
funders could mandate scientists to more freely share
protocols, implementation toolkits, or intervention web-
sites. Tools used in our review may inform such guide-
lines, including more routine application of Proctor,
Powell and colleague’s recommendations for tracking
and reporting implementation strategies [32, 34, 72] or
Stange and colleague’s conceptualization of contextual
factors [35–37]. Rather than reducing the nuances of im-
plementation in diverse, complex adaptive systems to
soundbites, we need to apply the principles of precision
medicine to research design to determine what works
for whom and why, rather than what works after vari-
ation has been removed. Funders and journal editors
should apply these policies so that investigation of how
intervention effects are modified by context and imple-
mentation strategies moves from being a “new methodo-
logical frontier” to a standard of practice for research
[86].
Conclusion
Multicomponent interventions can effectively increase
fecal testing for CRC across diverse rural and low-
income communities. Few community based studies
were effective, but this may be because they targeted pa-
tients irrespective of CRC screening eligibility. For
clinic-based studies, the intervention components fre-
quently found in highly effective and effective treat-
ment arms included mailing FIT/FOBT materials
directly to patient’s homes (i.e., “direct mail pro-
grams”), provision of a pre-addressed stamped
Davis et al. BMC Cancer  (2018) 18:40 Page 13 of 16envelope to facilitate kit return, client reminder and
recall, and provider ordered in-clinic distribution.
Based on the community guide, these strategies are
designed to improve community access by reducing
structural barriers and to increase community de-
mand. Few studies described contextual factors or im-
plementation strategies in the detail needed for
stakeholders to clearly determine how and which in-
terventions would work in their local contexts. More
robust application of guidelines to support reporting
of implementation strategies and contextual factors in
funding and publication are needed so that stake-
holders can determine not just which interventions
work to improve CRC screening, but which interven-
tions would work best in their setting given specific
patient populations, clinical settings, and community
characteristics.
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